•  
  •  
 

Central Asian Journal of Medicine

Abstract

The author outlines modern information on biological markers, which describe the diagnosis, assessment of its transmission, monitoring of the treatment process and the possible adverse effects of the disease. The article highlights the importance of biological markers in the early detection of various phenotypes of СHF.

First Page

65

Last Page

73

References

1. Ageyev F.Т., Arutyunov G.P., Belenkov Yu. N. i dr. Khronicheskaya serdechnaya nedostatochnost`. – М., «GEOTAR-Media».- 2010. –336 s. 2. Alyavi A.L., Kamilova U.K., Rasulova Z.D. Khronicheskaya serdechnaya nedostatochnost`. – Tashkent. – 2017 g. – 196 s. 3. Berezin А.Ye. Sistolicheskaya i diastolicheskaya serdechnaya nedostatochnost`: dve storoni` odnogo protsessa? Ukr. med. chasopis. - 2014; Т.3. – s.91-96. 4. Berezin А.Ye. Biologicheskiye markeri` kardiovaskulyarni`khzabolivaniy. Chast` 4. Diagnosticheskoye i prognosticheskoye znacheniye biomarkerov v stratifikatsii patsiyentov s serdechnoy nedostatochnost`yu. Lambert Academic Publishing GmbH. – Moskva. - 2015. – 329 s. 5. Berezikova Ye.N., Mayanskaya S.D., Garayeva L.А. i dr. Polimirfizm gena mozgovogo natriyureticheskogo peptida u bol`ni`kh s khronicheskoy serdechnoy nedostatochnost`yu // Kazanskiy meditsinskiy jurnal. - 2013. - №4. - s.433-438. 6. Drapkina О.М., Gegenava B.B. Fibroz miokarda u bol`ni`kh sakharni`m diabetom // Ratsional`naya farmakoterapiya v farmakologii. – 2013. – Тоm 9, №1. – s. 62 - 65. 7. Di`leva Yu.А., Gruzdeva О.V., Akbasheva О.Ye., Uchasova Ye.G., Fedorova N.V., Chernobay А.G., Karetkinova V.N., Kosareva S.N., Kashtalap V.V., Fedorova T.S., Barbarash О.L. Znacheniye stimuliruyushego faktora rosta ST2 i NT-proBNP v otsenke postinfarktnogo remodelirovaniya serdtsa. Rossiyskiy kardiologicheskiy jurnal. – 2015. – Т.12. – s. 63-71. 8. Svirida О.N. Ovchinnikov А.G., Ageyev F.T. Vliyaniye kandesartana i yego kombinatsii so spironolaktonom na diastolicheskuyu funktsiyu levogo jeludochka i soderjaniye biokhimicheskikh markerov balansa kollagena u patsiyentov s khronicheskoy serdechnoy nedostatochnost`yu i sokhranennoy sistolicheskoy funktsiyey levogo jeludochka // Jurnal serdechnaya nedostatochnost`. – 2010. – № 5. – s. 263 - 275. 9. Solomakhina N.I., Belenkov Yu.N. Prognosticheskoye znacheniye tkanevogo ingibitora matriksni`kh metalloproteinaz–I (TIMP–I) u bol`ni`kh KhSN // Jurnal serdechnaya nedostatochnost`. – 2010. – № 5. – s. 281–285. 10. AnjanV.Y., Loftus T.M., Burke M.A. et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic Peptide levels in heart failure with preserved ejection fraction // Am J Cardiol. – 2012. – Vol.110. - P. 870–876. 11. A. Gonzalez, B. Lopez, R. Querejeta [et al.]. Filling pressure and collagen metabolism in hypertensivepatients with heart failure and normal ejection fraction //Hypertension. – 2010. – Vol. 55, № 6. – Р. 1418–1424. 12. A. Maisel, C. Mueller, R. Nowak [et al.]. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: Results from the BACH (Biomarkers in Acute Heart Failure) trial // J. Am. Coll. Cardiol. – 2010. – Vol. 55, № 19. – P. 2062–2076. 13. Berk B.C., Fujiwara K., Lehoux S. ECM remodeling in hypertensive heart disease // J. Clin. Invest. – 2007. – Vol. 117. - №3. – Р. 568 – 75. 14. Braunwald E. Biomarkers in heart failure / E. Braunwald // N. Engl. J. Med. – 2008. – Vol. 358, № 20. – Р. 2148–2159. 15. Butler J., Fonarow G., Zile M. et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions // JACC Heart Fail. – 2014. №2. – P. 97–112. 16. Ciccone M.M., Cortese F., Gesualdo M., Riccardi R., Di Nunzio D., Moncelli M., Iacoviello M., Scicchitano P. A novel cardiac biomarker: ST2: a review. Molecules. – 2013. – Vol. 18, №12. – P. 15314-28. 17. Costello - Boerrigter L.C. , G. Boerrigter, S. Ameenuddin et al.The Effect of the Brain - Type Natriuretic Peptide Single - Nucleotide Polymorphism rs198389 on Test Characteristics of Common Assays // Mayo ClinProcv. - 2011. - Vol. 86. - №3. - P. 210-218. 18. Cuspidi C. et all. Hupertensive myocardial fibrosis // Nephrology Dialysis Transplantation. – 2006. – Vol. 21. - №1. – Р. 20 – 23. 19. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis inheart failure: systematic review and meta-analysis. J Card Fail. – 2007. № 13.- P. 599 - 608. 20. Dike B. Ojji, Lionel H. Opie, Sandrine Lecour, Lydia Lacerda, OlusojiAdeyemi, Karen Sliwa. Relationship Between Left Ventricular Geometry and Soluble ST2 in a Cohort of Hypertensive Patients. TheJournalofClinicalHypertension. – 2013.– Vol. 15. - №12. – Р. 899-904. 21. Dunlay S, Pereira N, Kushwaha S. Contemporary strategies in the diagnosis andmanagement of heart failure. Mayo Clin Proc. – 2014. Vol. 89. - №5. – P. 662-676. 22. Gaggin H. K., Motiwala S., Bhardwaj A., Parks K. A., Januzzi. Soluble Concentrations of the Interleukin Receptor Family Member ST2 and b-Blocker Therapy in Chronic Heart Failure. Circ Heart Fail. – 2013. – Vol. 6. - №6. – Р.1206-13. 23. Glean A.A., Ferguson S.K., HoldsworthC.T. et al. Effects of nitrite infusion on skeletal muscle vascular control during exercise in rats with chronic heart failure // Am. J. Physiol. Heart Circ. Physiol. – 2015. –Vol. 309. – P.1354–1360. 24. G.M. Felker, M. Fiuzat, L.K. Shaw [et al].Galectin - 3 in ambulatory patients with heart failure: results from the HF - ACTION study // Circ. HeartFail. – 2012. – Vol. 5, № 1. – Р. 72–78. 25. Joachim H., Michael G. Shlipak M., et all. Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease // J. Circulation. – 2007. – Vol. 115, № 12. – Р. 173-179. 26. J.E. Ho, C. Liu, A. Lyass [et al].Galectin - 3, a marker of cardiac fibrosis, predicts incident heart failure in the community// J. Am. Coll. Cardiol. – 2012. – Vol. 60, № 14. – Р. 1249–1256. 27. J.M. Cheng, K.M. Akkerhuis, L.C. Battes [et al.]. Biomarkers of heart failure with normal ejection fraction: a systematic review // Eur. J. Heart Fail. – 2013. – Vol. 15, № 12. – Р. 1350–1362. 28. J.Matsubara, S. Sugiyama, T. Nozaki [et al].Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction // J. Am. Coll. Cardiol. – 2011. – Vol. 57, № 7. – Р. 861–869. 29. Kevin Damman, Pim van der Harst,Tom D J Smilde, A. A. Voors, GerjanNavis, Dirk J van Veldhuisen,Hans L Hillege. Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure // Heart. - 2012; – Vol. 98. № 12. – Р. 319 – 324. 30. Lindenfeld J., Albert N.M., Boehmer J.P. et al. Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. J. Card. Fail. – 2010. – Vol.16. – P. 475-539. 31. Lupón J., GagginH.K., de Antonio M., Domingo M., Galán A., Zamora E., Vila J., Peñafiel J., Urrutia A., Ferrer E., Vallejo N., JanuzziJ.L., Bayes-Genis A. Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. Int J Cardiol. – 2015. – Vol. 184. – P. 337-43. 32. Michael G. Shlipak, Cristin C. Weekley,Yongmei Li, Lars - Olof Hansson, Anders Larsson, Mary Whooley. Comparison of Cardiovascular Prognosis by 3 Serum Cystatin C Methods in the Heart and Soul Study// Clinical Chemistry. - 2011; – Vol. 57: № 5. – Р. 737 – 745. 33. McMurray J.J. Clinical practice. Systolic heart failure. N. Engl. J. Med. – 2010. – Vol. 362. – P. 228-238. 34. McMurray J.J.V., Adamopoulos S., Anker S.D. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. – 2012. – Vol.33. – P.1787-1847. 35. Ohtani T., Mohammed S.F., Yamamoto K. Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodeling and poor outcomes in heart failure with preserved ejection fraction // Eur. Heart J. – 2012. – Vol. 33. – P. 1742–1749. 36. Paulus W.J., Tschоpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. – 2013. – Vol. 62. №4. – P. 263-271. 37. Ponikowski P., Voors A., Anker S. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2016: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2016 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC // Eur J Heart Fail. - 2016. - Vol 18. - P. 891–975. 38. RehmanS.U., Mueller T., JanuzziJ.L. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol. – 2008. – Vol. 52. №18. – P.1458–65. 39. R.A. de Boer, D.J. Lok, T. Jaarsma [et al]. Predictive value of plasma galectin -3 levels in heart failure with reduced and preserved ejection fraction // Ann. Med. – 2011. – Vol. 43, № 1. – Р. 60–68. 40. R.Pfister, S. Sharp, R. Luben et al. Mendelian Randomization Study of B-Type Natriuretic Peptide and Type 2 Diabetes: Evidence of Causal Association from Population Studies // P Lo S Medicine. – 2011. – Vol. 8, №10. – P. 1-11. 41. Vondráková D., Málek F., Ošt’ádal P., Kruger A., Neužil P. New biomarkers and heart failure. Coret Vasa. – 2013. -Vol. 55, №4. –P. 345-354. 42. Weir R.A., Miller A.M., Murphy G.E., Clements S., Steedman T., Connell J.M. et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am CollCardiol. – 2010. – Vol. 55, №3. – P.243-250. 43. YancyC.W., Jessup M., Bozkurt B. et al.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation /American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. – 2013. – Vol. 62, №16. – P. 147-239. 44. ZarebaK.M. Predictive value of admission electrocardiography in patients with heart failure / K.M. Zareba,H.J. Shenkman, J.D. Bibognano // Congest. Heart Fail. –2008. – Vol. 14, № 4. – Р. 173-179.

Share

COinS